HHS adds H5N1 clade 2.2 vaccine to stockpile

first_imgApr 29, 2008 (CIDRAP News) – The US Department of Health and Human Services (HHS) has accepted the first batch of H5N1 avian influenza vaccine based on the H5N1 variant known as clade 2.2, which has spread most widely across Asia, Europe, and Africa.Sanofi Pasteur announced yesterday that HHS is paying $192.5 million for the vaccine, which is being shipped in bulk form. The number of doses it represents will depend on the final formulation of the vaccine, but the amount could be used to make from 6.4 million to 38.5 million doses or more, the company said.”This acceptance represents the US government’s latest effort to diversify the vaccine stockpile program to include new strains of the H5N1 virus,” Sanofi said in a news release. The vaccine is based on H5N1 clade 2.2, the variant that caused the outbreak in bar-headed geese and other birds at China’s Quinghai Lake in 2005, the statement said. It was made at Sanofi’s plant in Swiftwater, Pa.Clade 2.2 viruses have sparked outbreaks in more than 60 countries in Africa, Asia, and Europe, with human cases in Azerbaijan, China, Djibouti, Egypt, Iraq, Nigeria, Pakistan, and Turkey, the World Health Organization reported in February.US officials hope that existing H5N1 vaccines will provide some protection for critical personnel in the early stages of a pandemic, should the H5N1 virus evolve into a pandemic strain. In a pandemic, it is expected to take several months to develop and start producing a vaccine closely matched to the new strain.Robin Robinson, PhD, director of HHS’s Biomedical Advanced Research and Development Agency (BARDA), confirmed that the supply received from Sanofi represents the first clade 2.2 vaccine to be added to the Strategic National Stockpile.Sanofi called the strain “particularly troubling because it is the first to be identified in an outbreak of migratory birds, which have the potential to spread the virus across continents.”Robinson told CIDRAP News the national stockpile already contains supplies of vaccine based on three other H5N1 variants: clade 1, clade 2.1, and clade 2.3. HHS has sought to diversify the stockpile out of concern that a vaccine based on one strain won’t work well against a pandemic virus stemming from a different strain.The stockpile was begun with a Sanofi vaccine based on a clade 1 virus from Vietnam, he said. In 2006 and 2007 HHS purchased vaccines based on clade 2.1, a strain identified in Indonesia, from Sanofi, GlaxoSmithKline (GSK), and Novartis, he reported. In addition, he said the agency has bought some vaccine from Novartis that’s based on clade 2.3, a strain from Anhui province in China.Robinson said the stockpile currently contains enough H5N1 vaccine to cover about 12 million to 13 million people, assuming two 90-microgram (mcg) doses per person. The vaccines are stored in bulk form, and it may be possible to use smaller doses if various trials of the vaccines with adjuvants (immune-boosting chemicals) are successful, he said.”This fall we should hit our goal [of having enough vaccine] for 20 million people,” Robinson said. “If the adjuvants become a reality we’ll be able to have more than that.” He reported that Sanofi vaccines make up about two thirds of the stockpile, while the GSK and Novartis vaccines account for about 17% each.Sanofi’s announcement yesterday said the clade 2.2 vaccine supplied to HHS would be good for 6.4 million 90-mcg doses. But if the amount could be reduced to 15 mcg per dose—the amount for each strain in seasonal flu vaccines—the supply would amount to 38.5 million doses.”If we had a really successful adjuvant, it could be even much higher than the numbers in the press release,” Sanofi spokesman Len Lavenda told CIDRAP News. He said the company is working on adjuvants.Robinson said HHS is supporting the development of adjuvants by GSK, Novartis, and Iomai Inc. Iomai’s adjuvant is delivered by a skin patch rather than by being mixed with the vaccine antigen and injected.The GSK and Novartis adjuvants for H5N1 vaccine “are in a very advanced stage of development in that they are hopefully going to submit licensure applications to the FDA [Food and Drug Administration] later this year,” Robinson said. He noted that the adjuvants are not licensed as separate products, but only in combination with a vaccine. If the adjuvanted vaccines are licensed, HHS can consider adding them to the national stockpile, he said.Robinson also said there are plans for a “mix and match” clinical trial in which Sanofi’s vaccine antigen will be combined with adjuvants from GSK and Novartis. The aim will be to see if the adjuvanted vaccines are safe and if they produce immune responses similar to those of the corresponding GSK and Novartis vaccines, he said.In addition, under an HHS contract, Sanofi will be testing split-virus and whole-virus H5N1 vaccines with two other adjuvants, involving aluminum hydroxide and an oil-and-water emulsion, Robinson said.See also: Apr 28 Sanofi Pasteur news releasehttp://en.sanofi.com/Images/14178_080428_HHS_H5N1_pdf.pdfWHO report on antigenic and genetic characteristics of H5N1 viruses, February 2008CIDRAP’s 2007 series on pandemic vaccine issues “The pandemic vaccine puzzle”Nov 20, 2006, CIDRAP News story “HHS awards contracts for more H5N1 vaccine”last_img read more

Equity performance squeezes Spanish pension fund returns in Q1

first_imgAt the end of March, total assets under management for Spain’s occupational pension funds stood at €35.3bn, a 1% reduction over the year.Figures from Mercer’s Pension Investment Performance Service (PIPS) backed up INVERCO’s findings, showing that Spanish pension funds lost 1.4% over the first three months of 2018. The PIPS survey covered a large sample of pension funds, most of them occupational schemes.According to the survey, equities as a whole incurred losses, with euro-zone equities down 2.9% and non-euro-zone holdings losing 3.3%.Non-euro-zone fixed income lost 3%, but euro-denominated debt delivered a 0.3% gain over the quarter. Non-eurozone assets as a whole were hit by the strengthening euro, Mercer said.The survey also showed that alternatives made a median loss of 0.4% while real estate was down by 0.1% over the quarter.In terms of asset allocation, domestic assets continued their gradual decline to 53.2% of portfolios at the end of March, according to INVERCO. Non-domestic assets continued to rise, from 29.6% at end-December 2017 to 31.3% three months later.Over the same period, average allocations to fixed income decreased slightly to 47%, while equities weightings rose to 34.6% on average.Spanish government bonds still made up the biggest single component of pension portfolios at 23.9%, with a further 13.8% in domestic corporate bonds.Xavier Bellavista, principal at Mercer, said: “The equity allocation is generally similar to what it was at end-2017, but it is remarkable that it has reached its highest since the period before the financial crisis in 2008.”According to Bellavista, Spanish pension funds maintain a percentage allocation in equity assets similar to those of pension funds in other European countries, but weightings are significantly different for bonds and alternatives.He said that within the fixed income allocation there had been a shift from domestic towards non-domestic assets.Bellavista added that Spanish funds were “still at the discussion stage” when it came to allocating more to alternatives. Poor first-quarter equity performance in 2018 has squeezed average returns from Spain’s occupational pension funds to 0.5% for the 12 months to end-March 2018, according to the country’s Investment and Pension Fund Association (INVERCO).This compared with a 3.2% return for the calendar year 2017, and a 5.6% return for the 12 months to end-March 2017.INVERCO said that equity markets had experienced pronounced corrections in the first three months of this year, prompting losses on pension fund portfolios with bigger equity exposures.This caused the average annualised returns for Spanish occupational funds to drop to 0.8% for the three years to 31 March 2018, and 4% over five years.last_img read more

Novatek expands LNG projects’ resource base

first_imgRussia’s largest independent natural gas producer Novatek has expanded its resource base for implementing its new liquefied natural gas (LNG) projects. The company said on Friday its two units, Arctic LNG-2 and Novatek-Yurkharovneftegas obtained new license areas in the Yamal and Gydan peninsulas.Arctic LNG-2 won the bid for a geological survey, exploration and hydrocarbons production license for the subsoil area including the Shtormovoye field, for a term of 30 years.The license area is located on the Gydan peninsula and is partly offshore in the Gydan and Ob bays in the Kara Sea bordering the company’s Utrennee field and contains estimated hydrocarbon resources of 7,932 mmboe according to the Russian resource classification.Novatek-Yurkharovneftegas won the bid for a geological survey, exploration and a 27-year hydrocarbons production license for the subsoil area including the Verhnetiuteyskoye and the West-Seyakhinskoye fields.The license area is located on the Yamal peninsula in close proximity to the South-Tambeyskoye field and contains estimated hydrocarbon resources of 8,747 mmboe according to the Russian resource classification.last_img read more

Bulldogs Battle Bulldogs In Swimming

first_imgBHS Swim results at Centerville 12/1/16.Girls Results.   Centerville-99 BHS 84Batesville is 6-1 on the season (3-0 EIAC), 3-1 non-conference).Boys Results.   Centerville 112, BHS-61Event Winners:   (G) Emily Gutzwiller (200 free/100 free), Mary Poltrack (100 fly/500 free), Hannah Cox (200 IM).  (B) Drake Main (100 back), Elliot Main (50 free).Career Best Times:  (G)Audra Brewer 100 breast, Ella Gutzwiller-50 back Kate Poltrack-200 free/500 free, Mary Poltrack 100 fly, Allison Storms 100 breast.  (B) Joseph Choi-200 IM, Caleb Rogers-100 fly, Skylar Simpson-100 back.Courtesy of Bulldogs Coach T. J. Greene.last_img